Circulating cell adhesion molecules as biomarkers in inflammatory bowel disease: a systematic review and meta-analysis
Open Access
- 1 December 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16
Abstract
Introduction: Endothelial dysfunction is a recognized component of the pathogenesis and clinical course of inflammatory bowel disease (IBD). Measurement of soluble forms of cell adhesion molecules (CAMs) may reflect the extent of endothelial injury and serve as potential biomarkers of disease activity. We conducted a systematic review and meta-analysis of studies reporting soluble intercellular adhesion molecule−1 (sICAM−1), vascular cell adhesion molecule−1 (sVCAM−1), mucosal addressin cell adhesion molecule−1 (sMAdCAM−1), and selectins (sE−selectin, sP−selectin, and sL−selectin) in patients with IBD and healthy controls, or in comparable IBD subgroups defined by disease activity or type. Methods: We systematically searched PubMed, Embase, Web of Science, and Scopus from inception to June 15, 2025. Risk of bias was assessed using a modified Newcastle–Ottawa Scale. Results: Twenty-six studies met the inclusion criteria. Compared with healthy controls, patients with IBD showed higher levels of sICAM-1 (SMD 1.38, 95% CI 0.51 to 2.25, p=0.002) and sE-selectin (SMD 0.35, 95% CI 0.09 to 0.61, p=0.008). In subgroup analyses, this association persisted for sICAM-1 in both Crohn’s disease (CD) (SMD 1.89, 95% CI 0.15 to 3.62, p=0.033) and ulcerative colitis (UC) (SMD 0.95, 95% CI 0.25 to 1.64, p=0.008), and for sE-selectin only in CD (SMD 0.43, 95% CI 0.04 to 0.82, p=0.032). When comparing active and inactive disease, higher sICAM-1 levels were observed in the active group (SMD 0.75, 95% CI 0.38 to 1.12, p<0.001), while no significant differences were found for other CAMs. No differences in levels of these molecules were observed between CD and UC. Conclusions: Circulating CAMs, particularly sICAM-1 and sE-selectin, are elevated in IBD patients, supporting a role of endothelial injury in disease pathogenesis. Among these, sICAM-1 shows potential as a biomarker for distinguishing active from inactive disease. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420251088622.Keywords
This publication has 76 references indexed in Scilit:
- ICAM-1 and VCAM-1: Gatekeepers in various inflammatory and cardiovascular disordersClinica Chimica Acta, 2023
- VCAM-1 as a predictor biomarker in cardiovascular diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2021
- ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesisJournal of Leukocyte Biology, 2020
- Distinct Chemokine Signaling Regulates Integrin Ligand Specificity to Dictate Tissue-Specific Lymphocyte HomingDevelopmental Cell, 2014
- Increased circulating platelet–neutrophil, platelet–monocyte complexes, and platelet activation in patients with ulcerative colitis: A comparative studyAmerican Journal of Hematology, 2006
- Soluble adhesion molecules in inflammatory bowel diseaseIrish Journal of Medical Science (1971 -), 2001
- Expression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel diseaseInflammation Research, 2000
- Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel diseaseJournal of Gastroenterology, 1997
- Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel diseaseDigestive Diseases and Sciences, 1994
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986